The febuxostat drug labels already carry a warning and precaution about cardiovascular events .
The clinical trials conducted before approval showed a higher rate of heart - related problems in patients treated with febuxostat compared to allopurinol .
The febuxostat drug labels already carry a warning and precaution about cardiovascular events because the clinical trials conducted before approval showed a higher rate of heart - related problems in patients treated with febuxostat compared to allopurinol .